protocolSection identificationModule nctId: NCT06355180, orgStudyIdInfo id: Shoudufazhan2024-1-2122, briefTitle: Esketamine Treatment for Depressive Episodes With Suicidal Ideation in Mood Disorders, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Capital Medical University, class: OTHER, collaborators name: Wuhu Fourth People's Hospital, collaborators name: The Second People's Hospital of Dali Bai Autonomous Prefecture, collaborators name: Inner Mongolia Autonomous Region Mental Health Center, collaborators name: Beijing Chaoyang District Third Hospital, collaborators name: Beijing Daxing District Xinkang Hospital, collaborators name: Capital's Funds for Health Improvement and Research, descriptionModule briefSummary: This study is a multicenter, non-inferiority, randomized, parallel-group, open-label clinical trial aimed at evaluating the effectiveness of esketamine versus modified electroconvulsive therapy (MECT) in treating suicidal ideation during depressive episodes of mood disorders. Additionally, it seeks to explore the potential mechanisms of esketamine's anti-suicidal effects., conditionsModule conditions: Mood Disorders, conditions: Suicidal Ideation, conditions: Depressive Episode, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Patients will be randomized to either the esketamine group or the MECT group, but due to the differences in treatment modalities, it will not be possible to blind the subjects and investigators. To ensure the objectivity of the measurements, independent assessors will be established. These assessors are psychiatrists trained in the consistency of the scales and will remain blinded to the group allocation of the subjects throughout the entire assessment process., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 340, type: ESTIMATED, armsInterventionsModule interventions name: Subanesthetic dose intravenous esketamine, interventions name: Modified electroconvulsive therapy, outcomesModule primaryOutcomes measure: Suicide remission rate based on the Scale for Suicidal Ideation (SSI), secondaryOutcomes measure: Quick Inventory of Depressive Symptoms Self Report (QIDS-SR), secondaryOutcomes measure: Columbia Suicide Severity Rating Scale (CSSR-S), secondaryOutcomes measure: Montgomery Asberg Depression Rating Scale (MADRS), secondaryOutcomes measure: Clinical Global Impressions(CGI), secondaryOutcomes measure: Short Form 12 Health Survey(SF-12), secondaryOutcomes measure: Sheehan Disability Scale(SDS), secondaryOutcomes measure: Digital Span Test(DST), secondaryOutcomes measure: Digit Symbol Substitution Test(DSST), secondaryOutcomes measure: Perceived Deficit Questionnaire for Depression 5-item(PDQ-D-5), secondaryOutcomes measure: Young Mania Rating Scale (YMRS), secondaryOutcomes measure: Clinician Administered Dissociative States Scale(CADSS), secondaryOutcomes measure: Adverse event, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False